1. T3 Type 2 diabetic hearts are energetically defective both globally and at the level of the mitochondria. (26th October 2016) Authors: Kerr, M; Fialho, MS; Tyler, D; Heather, LC Journal: Heart Issue: Volume 102(2016)Supplement 8 Page Start: A1 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. P6 Fatty acids impair HIF1α activation and suppress metabolic adaptation to hypoxia in insulin resistance. (26th October 2016) Authors: Dodd, MS; Luiken, JJFP; Glatz, JFC; Tyler, DJ; Heather, LC Journal: Heart Issue: Volume 102(2016)Supplement 8 Page Start: A3 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. P9 HIF activator DMOG improves functional recovery following ischaemia-reperfusion in the type 2 diabetic heart. (26th October 2016) Authors: Fialho, MdL Sousa; Thompson, HEC; Dodd, M; Ball, V; Carr, CA; Tyler, DJ; Heather, LC Journal: Heart Issue: Volume 102(2016)Supplement 8 Page Start: A4 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. P27 Depletion of cardiac succinate mediates impaired hypoxia-inducible factor 1Α signalling by long chain fatty acids in insulin resistance. (21st March 2018) Authors: Dodd, MS; Sousa Fialho, Mdl; Montes Aparico, CN; Kerr, M; Timm, KN; Griffin, JL; Luiken, JJFP; Glatz, JFC; Tyler, DJ; Heather, LC Journal: Heart Issue: Volume 104(2018)Supplement 3 Page Start: A11 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. P35 Treatment with oleic acid and a pparα agonist increases fatty acid oxidation in beating human inducible pluripotent stem cell-derived cardiomyocytes. (21st March 2018) Authors: Al-Siddiqi, H; Lopez, CA; Heather, LC; Carr, CA Journal: Heart Issue: Volume 104(2018)Supplement 3 Page Start: A13 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. 2 Pharmacological inhibition of sarcolemmal fatty acid uptake provides a novel mechanism to improve metabolism and function in the type 2 diabetic heart. (17th November 2015) Authors: Fialho, MdL Sousa; Mansor, LM; Yea, G; Evans, RD; Coumans, WA; Luiken, JJ; Glatz, J; Tyler, DJ; Heather, LC Journal: Heart Issue: Volume 101(2015)Supplement 6 Page Start: A1 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. P33 Pharmacological stimulation of HIF signalling as a potential treatment approach for the type 2 diabetic heart. (21st March 2018) Authors: Sousa Fialho, MdL; Kerr, M; Dodd, MS; Montes Aparicio, C; Tyler, DJ; Heather, LC Journal: Heart Issue: Volume 104(2018)Supplement 3 Page Start: A13 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗